Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Equity Average (2016 - 2025)

Lineage Cell Therapeutics' Equity Average history spans 15 years, with the latest figure at $32.1 million for Q4 2025.

  • For Q4 2025, Equity Average fell 54.77% year-over-year to $32.1 million; the TTM value through Dec 2025 reached $32.1 million, down 54.77%, while the annual FY2025 figure was $60.2 million, 13.43% down from the prior year.
  • Equity Average reached $32.1 million in Q4 2025 per LCTX's latest filing, down from $34.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $121.6 million in Q3 2021 to a low of $32.1 million in Q4 2025.
  • Average Equity Average over 5 years is $76.5 million, with a median of $70.7 million recorded in 2023.
  • Peak YoY movement for Equity Average: grew 29.44% in 2021, then crashed 54.77% in 2025.
  • A 5-year view of Equity Average shows it stood at $105.2 million in 2021, then decreased by 28.98% to $74.7 million in 2022, then fell by 13.92% to $64.3 million in 2023, then grew by 10.2% to $70.9 million in 2024, then plummeted by 54.77% to $32.1 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Equity Average are $32.1 million (Q4 2025), $34.0 million (Q3 2025), and $62.4 million (Q2 2025).